Trial Profile

A Clinical Trial to Investigate SL-1001

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2019 New trial record
11 Mar 2019 According to a Stemline Therapeutics media release, the company has exclusively licensed worldwide rights to develop and commercialize SL-1001 from the CRT Pioneer Fund LP, a pound 70 million specialist oncology investment fund managed by Sixth Element Capital, a UK based fund manager.
11 Mar 2019 According to a Stemline Therapeutics media release, SL-1001 is expected to enter the clinic in 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com